

**Date: 14<sup>th</sup> February, 2019**

To,  
Listing Department,  
BSE Limited  
Floor 25, PJ Tower  
Dalal Street,  
Mumbai – 400 001  
Script Code: 540359

**Sub.: Outcome of the proceedings of the meeting of the Board of Directors  
of the Company**


Dear Sirs,

This is to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 14<sup>th</sup> February, 2019, inter—alia, considered and approved the Unaudited Financial Results for quarter and Nine Months ended 31st December, 2018. The same has also been reviewed by the Audit Committee in its meeting held today.

A copy of the Statement of Unaudited Financial Results for the quarter and half year ended 31st December, 2018, approved by the Board pursuant to Regulation 33 of the Securities And Exchange Board of India (LODR Regulations, 2015), is enclosed for your reference and record. A copy thereof has also been sent for publication as per the requirements. The meeting commenced at 1:00 pm. and concluded 4:30 pm.

We would like to submit that M/ s. B A Shah S R Mehta & Co., Statutory Auditors of Company have carried out limited review of Unaudited Financial Results for quarter and Nine Months ended 31st December, 2018 and Board has also taken on record their Limited Review Report on said Results.

**For, Parmax Pharma Limited**

  
**Yash J. Vora**  
**Company Secretary**



## Statement of Standalone Unaudited Results for the Quarter and Nine Months Ended 31.12.2018

(in Rs.)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	18686906	35350685	25785127	87865033	87423921	119015986
II.	Other income	67258	44316	45882	154168	291133	472423
III.	<b>Total Income (I+II)</b>	<b>18754164</b>	<b>35395001</b>	<b>25831009</b>	<b>88019201</b>	<b>87715054</b>	<b>119488409</b>
IV.	<b>Expenses</b>						
	(a) Cost of materials consumed	9207125	12823730	16963439	37274521	57356065	70645775
	(b) Purchase of stock-in-trade	0	0	0	0	0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-1295207	13093023	-7268692	14510330	-9071580	-12830395
	(d) Employee benefits expense	5352005	5214196	6574520	15471167	18607147	21313498
	(e) Finance Costs	37035	271569	91962	373718	278843	335776
	(f) Depreciation and amortisation expense	2595586	2595337	2615600	7743023	7826600	10929861
	(g) Other expenses	5771995	6941907	6485151	20491442	15541237	29077352
	<b>Total expenses (IV)</b>	<b>21668539</b>	<b>40939762</b>	<b>25461980</b>	<b>95864201</b>	<b>90538312</b>	<b>119471867</b>
V.	<b>Profit/(Loss) from operations before exceptional items and tax (I-IV)</b>	<b>-2914375</b>	<b>-5544761</b>	<b>369029</b>	<b>-7845000</b>	<b>-2823258</b>	<b>16542</b>
VI.	Exceptional Items	0	0	0	0	0	0
VII.	<b>Profit/ (Loss) before tax (V-VI)</b>	<b>-2914375</b>	<b>-5544761</b>	<b>369029</b>	<b>-7845000</b>	<b>-2823258</b>	<b>16542</b>
VIII.	Tax expense:						
	(1) Current tax	0	0	0	0	0	250000
	(2) Deferred tax	0	0	0	0	0	238884
IX.	<b>Net Profit / (Loss) for the period from continuing operations (VII-VIII)</b>	<b>-2914375</b>	<b>-5544761</b>	<b>369029</b>	<b>-7845000</b>	<b>-2823258</b>	<b>5426</b>
X.	<b>Profit/(loss) from discontinued operations</b>						
XI.	Tax expense of discontinued operations	0	0	0	0	0	0
XII.	<b>Profit/(loss) from Discontinued operations (after tax) (X-XI)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
XIII.	<b>Profit (Loss) for the period (IX+XII)</b>	<b>-2914375</b>	<b>-5544761</b>	<b>369029</b>	<b>-7845000</b>	<b>-2823258</b>	<b>5426</b>
XIV.	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0	0	0
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV.	<b>Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)</b>	<b>-2914375</b>	<b>-5544761</b>	<b>369029</b>	<b>-7845000</b>	<b>-2823258</b>	<b>5426</b>
XVI.	<b>Paid-up equity share capital (Face Value Rs 10)</b>	<b>37413000</b>	<b>37413000</b>	<b>37413000</b>	<b>37413000</b>	<b>37413000</b>	<b>37413000</b>
XVII.	<b>Earnings per share (for continuing operation &amp; discontinuing operation) (of Rs. 10/- each ):</b>						
	(a) Basic	-0.78	-1.48	0.10	-2.10	-0.75	0.00
	(b) Diluted	-	-	-	-	-	-

**Notes:**

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14.02.2019
2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and half year ended 31st December, 2018
3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
4. Statement of Unaudited Financial Results of the company for the Quarter and half ended 31st December, 2018, in the prescribed format under Schedule III of Companies Act, 2013
5. The figures for the previous period have been regrouped wherever necessary.

FOR, PARMAX PHARMA LIMITED

*Alkesh Gosalia*

Place Hadamtala (Rajkot)  
Date: 14.02.2019

Alkesh Gosalia  
Director

